Interim Analysis of a Phase III Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine vs. Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer. A Southern Italy Cooperative Oncology Group Study
Pasquale Comella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Comella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), S. Mancarella(Radiation Oncology Institute), G.P. Nicolella(Radiation Oncology Institute), E Micillo(Medical Center Hospital), Alfredo Lamberti(Medical Center Hospital), R Cioffi(Medical Center Hospital), A. Di Nota(Medical Center Hospital), Michèle Natale(Medical Center Hospital), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Luigi Manzione, Vito Lorusso, Giuseppe De Cataldis(Radiation Oncology Institute), Luigi Maiorino(Medical Center Hospital), Nicola Panza(Radiation Oncology Institute), G. Frasci(Radiation Oncology Institute)
Cited by 10
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
|Journal of Clinical Oncology|2000|177
Lapatinib in breast cancer
|Annals of Oncology|2007|129
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108